What is ARMP's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.13B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ARMP?

P/E (TTM) is n/a and 52-week range is $3.09 to $16.34 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ARMP figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ARMP?

The company profile lists revenue (TTM) near $3M, net income (TTM) near $-11.37B, EPS (TTM) near $-6.12 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Armata Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Los Angeles, California, US, 36.7M shares outstanding, ISIN US04216R1023 when available from company profile and filing metadata.

Chartloom

Please enable JavaScript to continue using this application.

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Los Angeles, California and currently employs 61 full-time employees. The firm is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. The company is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

Employees

Website

www.armatapharma.com/

IPO

1994-05-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)